The company credited its molecular diagnostics and international businesses as drivers of new growth.
Enzo's patent relates to modified nucleotides for diagnostic and therapeutic applications, and is central to separate ongoing lawsuits with diagnostic developers.
The firm said that its Panther Fusion system expands molecular testing capabilities, and increases productivity and flexibility for labs.
The Aptima HSV 1 & 2 nucleic acid amplification test qualitatively detects and differentiates between HSV-1 and HSV-2 on the automated Panther system.
Despite strong molecular diagnostics product sales growth, the firm's overall diagnostics business was down almost 3 percent year over year.
Hologic said that HCV therapeutic options are evolving rapidly, and the approval will enable physicians to quickly decide on the best treatments.
The firm reported continued strength for MDx product sales across its women's health business and an overall return to growth in international sales.
Hologic's CEO said in December that the blood screening business was a drag on the company's growth.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
